Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Informationsteknik |
| Industri | Programvara |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Aiforia Technologies Plc, Company announcement, 5 February 2026 at 08:00 a.m. EET
Aiforia Technologies Plc: Share subscriptions based on stock options 2016 A, 2019 I and 2021 IV
A total of 85,000 Aiforia Technologies Plc’s new shares has been subscribed for with the stock options 2016 A, 2019 I and 2021 IV on 7 January 2026. For subscriptions made with the stock options 2016 A, 2019 I and 2021 IV and the entire subscription price of EUR 82,844.00 will be entered in the reserve for invested unrestricted equity.
After entering the Trade Register, the total number of shares is 33,691,604.
The new shares subscribed for under the stock options 2016 A, 2019 I and 2021 IV have been registered in the Trade Register on 5 February 2026, as of which date the new shares will establish shareholder rights.
The shares will be traded in the Nasdaq Helsinki Plc’s First North Growth Market Finland -marketplace as an additional lot with the company’s old shares as of 6 February 2026.
The terms and conditions of stock options programs are available on the company's website at https://www.aiforia.com/.
For further information, please contact:
Further inquiries
Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc
tel. +358 405 009 878
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.
Find out more at www.aiforia.com